Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

RBNZ reopens Wellington office after asbestos mayhem
Finance

RBNZ reopens Wellington office after asbestos mayhem

Bank tight-lipped on how many staff are home-working as asbestos-hit office reopens. 

Oceania Healthcare extends dividend freeze
Markets

Oceania Healthcare extends dividend freeze

The retirement village operator hasn't paid a dividend since June 2023.

Reform wave reshapes energy sector as investors circle NZ
Infrastructure

Reform wave reshapes energy sector as investors circle NZ

Nearly half of surveyed offshore investors planning an acquisition.